Watch ImStem’s scientists introduce its innovative stem cell technology on Bloomberg
News Center
First US Patient Dosed With Investigational Stem Cell Therapy IMS001 for MS
11/23 . 2021
The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
-
05 2022.06
-
31 2022.05
-
18 2021.11
ImStem Announces First US Multiple Sclerosis Patient Has Been Dosed with its IMS001
ImStem Biotechnology today announces the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
-
18 2021.11
TIP Company ImStem Biotechnology Doses First MS Patient in Clinical Trial
UConn TIP company ImSTEM Biotechnology is conducting a clinical trial to test their experimental human embryonic stem cell-derived mesenchymal stem cell therapy for the treatment of multiple sclerosis.